Study of study drug with other treatments for advanced solid tumors
Treatments studied
Part of Cancer clinical trials.
This trial is testing a new drug, MK-2010, alone or with other treatments for people with advanced solid tumors. The goal is to learn if it is safe and effective. Participants should be in fairly good health despite their cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced solid tumors that can be seen on imaging scans.
- You can swallow and hold down oral medication, and your stomach and intestines work normally.
- If you have HIV, your HIV is well-controlled with anti-HIV medicine.
- Your major organs (like liver, kidneys, heart) are working well enough.
- You are not on blood thinners (anticoagulants).
- You have not had certain serious health problems like heart failure, seizures, or lung inflammation in the past.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an investigational drug called MK-3120 for people with advanced solid tumors (cancer that has spread or cannot be removed). It is for patients whose cancer has progressed after standard treatments, and it aims to see if the drug is safe and effective.
This trial tests a new drug combination for people with advanced solid tumors. It aims to see if the combination is safe and may shrink tumors.
This trial tests an investigational drug called MK-2750 for people with certain advanced cancers that have spread or cannot be removed by surgery. The goal is to see if the drug can shrink tumors or slow their growth.
This study tests a new experimental drug called MK-6204 (also known as SKB535) to see if it is safe and effective for people with certain advanced cancers that have not responded to standard treatments. The drug is given by injection and may help shrink tumors or slow their growth.
This trial tests a new drug, MK-4716, alone or with cetuximab or pembrolizumab, for people with advanced solid tumors that have a specific KRAS gene change. It aims to see if the drug can shrink tumors or slow their growth.
This study tests an investigational drug, GSK5533524, either alone or with other treatments, in adults with advanced solid tumors that have stopped responding to standard therapies. The goal is to find a safe dose and see if it helps shrink or control the tumor.
Hear when a new Malignant Neoplam trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.